Digital Is DTx finally reaching drug-like efficacy? A Q&A with David... Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.
Digital Molecules, DTx, and a breakthrough in chronic cough Early evidence for a cough treatment digital therapeutic is compelling.
Digital Transforming Pharma: Insights from Frontiers Health 2025 pharmaphorum caught up with Emre Ozcan (Merck Group) after his onstage session at Frontiers Health.
Digital Ten years of innovation at Frontiers Health – Live from Berl... Tune into a wrap-up podcast from Frontiers Health 2025, with Jonah Comstock, Nicole Raleigh, and Jessica DaMassa.
News Boehringer, Click DTx for schizophrenia clears pivotal trial Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.
News Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira Lumos Labs has secured its first 510(k) clearance for a digital therapeutics offering, paving the way for entrance into the regulated app market.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.